Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 24 of 751 for:    Area Under Curve AND meal

Genetic and Metabolism of Post-prandial HDL Particles (HDL-PP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03109067
Recruitment Status : Completed
First Posted : April 12, 2017
Last Update Posted : April 12, 2017
Sponsor:
Information provided by (Responsible Party):
Institut National de la Santé Et de la Recherche Médicale, France

Brief Summary:
Reverse cholesterol transport (RCT) pathway explains the anti-atherosclerosis role of HDL. Post prandial hypertriglyceridemia is highly predictive of atherosclerosis. TaqIB polymorphism in CETP gene plays a role on HDL particles, and might give a link between TaqIB polymorphism and the cardioprotective efficiency of HDL particles. Our main objective was to compare post-prandial HDL particles between patients having B2 allele carriers (genotype AA) to B1 allele carriers (genotype GG), and their ability to mediate cellular cholesterol efflux, via SR-BI Scavenger Receptor class B type I (SR-BI) , ABCG1 and ABCA1 pathways.

Condition or disease Intervention/treatment Phase
Healthy Volunteers Other: Standardized meal Not Applicable

Detailed Description:

Background:

This trial focuses on anti-atherogenic properties functions of HDL lipoproteins, particularly those linked to reverse transport cholesterol (RCT) pathway, genetic factors involved in plasmatic HDL-C and post-prandial metabolism. The post-prandial period is associated with an activation of the RCT with an increase in Cholesteryl ester transfer protein (CETP), in plasmatic HDL particles. There is also an increase of HDL particles ability to mediate cellular cholesterol efflux, via SR-BI and ABCG1 pathways. TaqIB polymorphism is associated with a variation of the plasma to mediate cellular cholesterol efflux.

Aim of the study:

The investigators were aiming to test the hypothesis that the genetic variability of HDL-C is associated with structural and functional variability of post-prandial HDL particles and particularly in their ability to mediate the initial step of RCT.

Intervention:

The study aimed to include n=50 patients with a TaqIB AA polymorphism and 50 patients with a GG TaqIB polymorphism. Blood samples were performed fasted, before and after intake of a standardized test meal at 5 different time : H0 before the meal, H2, H4, H6 and H8 after the meal.

Explorations:

For the fasted sample a full lipidic assessment was performed including the dosing of: triglyceridemia, HDL-C, apolipoprotein B (apoB), apolipoprotein AI. The plasmatic kinetic of triglyceridemia, apoB100, apo-48 and the activity of CETP was performed on each sample.

HDL particles were also explored with qualitative and quantitative assessment of the HDL fractions ability to mediate cholesterol efflux via each pathway : SR-BI, ABCA1 and ABCG1 in our cellular models.

The study therefore aimed to improve our knowledge of molecular mechanisms involved in HDL particles dysfunction in metabolic diseases.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 100 participants
Intervention Model: Single Group Assignment
Intervention Model Description: Same intervention for everyone, two different groups
Masking: None (Open Label)
Primary Purpose: Screening
Official Title: Influence of TaqIB (rs708272) Polymorphism in Cholesteryl Ester Transfer Protein (CETP) Gene on Functionality of HDL Particles, in the Pathway of Reverse Transport of Fasting and Post-prandial Cholesterol.
Actual Study Start Date : September 21, 2011
Actual Primary Completion Date : November 21, 2015
Actual Study Completion Date : November 21, 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Standardized meal

Standardized meal for :

50 patients with a TaqIB AA polymorphism 50 patients with a TaqIB GG polymorphism

Other: Standardized meal
Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal




Primary Outcome Measures :
  1. Comparison of post-prandial HDL particles [ Time Frame: before the meal (time = 0 hour) vs 2 hours after ]
    Compare post-prandial HDL particles area under curve (AUC) between patients having B2 allele carriers (genotype AA) to B1 allele carriers (genotype GG)


Secondary Outcome Measures :
  1. Comparison of post-prandial HDL particles [ Time Frame: before the meal (time = 0 hour), 2 hours, 4 hours, 6 hours and 8 hours after the meal ]
    Compare post-prandial HDL particles area under curve (AUC) between patients having B2 allele carriers (genotype AA) to B1 allele carriers (genotype GG), and their ability to mediate cellular cholesterol efflux, via SR-BI, ABCG1 and ABCA1 pathways.

  2. Efflux capacity of postprandial HDL particles [ Time Frame: before the meal (time = 0 hour), 2 hours, 4 hours, 6 hours and 8 hours after the meal ]
    - Compare the increase of efflux capacity of postprandial HDL particles between individuals harboring a B2 allele compared to those harboring a B1 allele.

  3. Area under curves of triglyceridemia of apoB100 and apoB48 [ Time Frame: before the meal (time = 0 hour), 2 hours, 4 hours, 6 hours and 8 hours after the meal ]
    Compare area under curves of triglyceridemia of apoB100 and apoB48 between individuals harboring a B2 allele (genotype AA) in the TaqIB polymorphism of the CETP gene.

  4. Plasmatic concentrations of apoB100 [ Time Frame: before the meal (time = 0 hour), 2 hours, 4 hours, 6 hours and 8 hours after the meal ]
    Compare plasmatic concentrations of apoB100 between individuals harboring a B2 allele (genotype AA) in the TaqIB polymorphism of the CETP gene.

  5. Correlation between the area under curve of triglyceridemia and the efflux capacity of HDL particles. [ Time Frame: before the meal (time = 0 hour), 2 hours, 4 hours, 6 hours and 8 hours after the meal ]
    Investigate the correlation between the area under curve of triglyceridemia and the efflux capacity of HDL particles.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Affiliation to a national social security scheme
  2. Age between 18 and 60 years old
  3. Male subjects
  4. Participants harboring either a B2 (genotype AA) allele or a B1 (genotype GG) in TaqIB polymorphism of CETP gene
  5. Fasted plasmatic triglyceridemia < 300 mg/dL
  6. Free prior and informed written consent given by the participant

Exclusion Criteria:

  1. Participants with an history of symptomatic cardio-vascular disease (infarct, angina pectoris, acute coronary syndrome, cardiac surgery, endoluminal coronal intervention, stroke, symptomatic peripheral artery disease) within 6 months prior to inclusion.
  2. Triglyceridemia > 3 g/L
  3. Participants having other lipid-lowering agents than statin (fibrate, niacin, ezetimibe)
  4. Participants having a treatment (either systemic or local) which might interfere with the evaluation of study parameters.
  5. Excessive alcohol consumption, or any drug addiction. An excessive alcohol consumption is superior to 21 time 30 mL of alcohol or 120 mL of wine or 355 mL of beer.
  6. Regular smoker or smoking cessation within the last year
  7. Significant abnormality on the full blood count or plasmatic and urinary biochemistry analysis.
  8. Chronic or acute disease either life threatening or able to modify study results, including among others :

    1. Diabetes
    2. Renal diseases : nephrotic syndrome, chronic kidney failure and/or creatininemia > 1.7 time the upper limit of normal (ULN).
    3. Hypothyroidism defined by thyroid-stimulating hormone > 2x ULN
    4. Hepatobiliary disease or viral hepatitis B or C confirmed by transaminases > 2x ULN or alkaline phosphatase > 1.5x ULN or total bilirubinemia > 1.5x ULN at screening.
    5. Known HIV
    6. Gastro-intestinal disorder or disease that might modify intestinal absorption, bariatric surgery.
  9. Participant who might interfere with the quality of the study or might compromise the study according to the investigator.
  10. Participant currently enrolled in another study or in the exclusion period of another study.
  11. Participants with uncontrolled hypertension defined by a systolic blood pressure > 140 mmHg or a diastolic blood pressure > 90 mmHg.
  12. Participants with a C reactive protein (CRP) > 5mg/L
  13. Participants with a E2/E2 phenotype of apolipoprotein E.
  14. Blood donation or product derived-from blood donation within the last 3 months prior to the test meal.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03109067


Locations
Layout table for location information
France
Centre d'Investigation Clinique Paris Est
Paris, France, 75013
Sponsors and Collaborators
Institut National de la Santé Et de la Recherche Médicale, France
Investigators
Layout table for investigator information
Study Director: Karim Ammour Institut National de la Santé Et de la Recherche Médicale, France

Layout table for additonal information
Responsible Party: Institut National de la Santé Et de la Recherche Médicale, France
ClinicalTrials.gov Identifier: NCT03109067     History of Changes
Other Study ID Numbers: C10-57
First Posted: April 12, 2017    Key Record Dates
Last Update Posted: April 12, 2017
Last Verified: January 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Institut National de la Santé Et de la Recherche Médicale, France:
Cholesterol, HDL, Postprandial Period, Polymorphism, Genetic